211 related articles for article (PubMed ID: 28745238)
1. Effect of Number of Bifunctional Chelating Agents on the Pharmacokinetics and Immunoreactivity of 177Lu-labeled Rituximab: A Systemic Study.
Guleria M; Das T; Kumar C; Sharma R; Amirdhanayagam J; Sarma HD; Dash A
Anticancer Agents Med Chem; 2018; 18(1):146-153. PubMed ID: 28745238
[TBL] [Abstract][Full Text] [Related]
2. Comparative Evaluation of Using NOTA and DOTA Derivatives as Bifunctional Chelating Agents in the Preparation of
Guleria M; Das T; Amirdhanayagam J; Sarma HD; Dash A
Cancer Biother Radiopharm; 2018 Feb; 33(1):8-16. PubMed ID: 29373046
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.
Chauhan SC; Jain M; Moore ED; Wittel UA; Li J; Gwilt PR; Colcher D; Batra SK
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):264-73. PubMed ID: 15791435
[TBL] [Abstract][Full Text] [Related]
4. Impact of DOTA-Chelators on the Antitumor Activity of
Wojdowska W; Karczmarczyk U; Balog L; Sawicka A; Pöstényi Z; Kovács-Haász V; Polyák A; Laszuk E; Mikołajczak R; Garnuszek P
Cancer Biother Radiopharm; 2020 Oct; 35(8):558-562. PubMed ID: 32255676
[No Abstract] [Full Text] [Related]
5. Development and biological studies of ¹⁷⁷Lu-DOTA-rituximab for the treatment of Non-Hodgkin's lymphoma.
Massicano AV; Pujatti PB; Alcarde LF; Suzuki MF; Spencer PJ; Araújo EB
Curr Radiopharm; 2016; 9(1):54-63. PubMed ID: 25771373
[TBL] [Abstract][Full Text] [Related]
6. Preparation of clinical-scale
Guleria M; Das T; Kumar C; Amirdhanayagam J; Sarma HD; Banerjee S
J Labelled Comp Radiopharm; 2017 May; 60(5):234-241. PubMed ID: 28181275
[TBL] [Abstract][Full Text] [Related]
7. Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma.
Repetto-Llamazares AH; Larsen RH; Patzke S; Fleten KG; Didierlaurent D; Pichard A; Pouget JP; Dahle J
PLoS One; 2015; 10(6):e0128816. PubMed ID: 26066655
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of 177Lu-DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties.
Knogler K; Grünberg J; Novak-Hofer I; Zimmermann K; Schubiger PA
Nucl Med Biol; 2006 Oct; 33(7):883-9. PubMed ID: 17045168
[TBL] [Abstract][Full Text] [Related]
9. Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates.
Ghosh SC; Pinkston KL; Robinson H; Harvey BR; Wilganowski N; Gore K; Sevick-Muraca EM; Azhdarinia A
Nucl Med Biol; 2015 Feb; 42(2):177-83. PubMed ID: 25457653
[TBL] [Abstract][Full Text] [Related]
10. Comparison of (64)Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro/in vivo stability.
Cooper MS; Ma MT; Sunassee K; Shaw KP; Williams JD; Paul RL; Donnelly PS; Blower PJ
Bioconjug Chem; 2012 May; 23(5):1029-39. PubMed ID: 22471317
[TBL] [Abstract][Full Text] [Related]
11. Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy.
Pan MH; Gao DW; Feng J; He J; Seo Y; Tedesco J; Wolodzko JG; Hasegawa BH; Franc BL
Mol Imaging Biol; 2009; 11(3):159-66. PubMed ID: 19034582
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of Site-Specific Radiolabeled Antibodies for Radioimmunotherapy via Genetic Code Expansion.
Wu Y; Zhu H; Zhang B; Liu F; Chen J; Wang Y; Wang Y; Zhang Z; Wu L; Si L; Xu H; Yao T; Xiao S; Xia Q; Zhang L; Yang Z; Zhou D
Bioconjug Chem; 2016 Oct; 27(10):2460-2468. PubMed ID: 27617674
[TBL] [Abstract][Full Text] [Related]
13. In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications.
Milenic DE; Garmestani K; Chappell LL; Dadachova E; Yordanov A; Ma D; Schlom J; Brechbiel MW
Nucl Med Biol; 2002 May; 29(4):431-42. PubMed ID: 12031878
[TBL] [Abstract][Full Text] [Related]
14. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
15. Blood pharmacokinetics of various monoclonal antibodies labeled with a new trifunctional chelating reagent for simultaneous conjugation with 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid and biotin before radiolabeling.
Wang Z; Mårtensson L; Nilsson R; Bendahl PO; Lindgren L; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7171s-7177s. PubMed ID: 16203818
[TBL] [Abstract][Full Text] [Related]
16. Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ⁹⁰Y and ¹¹¹In for domestic radioimmunotherapy and radioscintigraphy of non-Hodgkin's lymphoma.
Gholipour N; Jalilian AR; Khalaj A; Johari-Daha F; Yavari K; Sabzevari O; Khanchi AR; Akhlaghi M
Daru; 2014 Jul; 22(1):58. PubMed ID: 25074720
[TBL] [Abstract][Full Text] [Related]
17. In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study.
Forrer F; Chen J; Fani M; Powell P; Lohri A; Müller-Brand J; Moldenhauer G; Maecke HR
Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1443-52. PubMed ID: 19350237
[TBL] [Abstract][Full Text] [Related]
18. Does the Number of Bifunctional Chelators Conjugated to a mAb Affect the Biological Activity of Its Radio-Labeled Counterpart? Discussion Using the Example of mAb against CD-20 Labeled with
Karczmarczyk U; Sawicka A; Garnuszek P; Maurin M; Wojdowska W
J Med Chem; 2022 May; 65(9):6419-6430. PubMed ID: 35442675
[TBL] [Abstract][Full Text] [Related]
19. Studies on efficacy of a novel 177Lu-labeled porphyrin derivative in regression of tumors in mouse model.
Sarma HD; Das T; Banerjee S; Venkatesh M; Vidyasagar PB; Mishra KP
Curr Radiopharm; 2011 Apr; 4(2):150-60. PubMed ID: 22191655
[TBL] [Abstract][Full Text] [Related]
20. Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands.
Hens M; Vaidyanathan G; Welsh P; Zalutsky MR
Nucl Med Biol; 2009 Feb; 36(2):117-28. PubMed ID: 19217523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]